Marcocci Elena, Uliana Vera, Bruttini Mirella, Artuso Rosangela, Silengo Margherita Cirillo, Zerial Marlenka, Bergesio Franco, Amoroso Antonio, Savoldi Silvana, Pennesi Marco, Giachino Daniela, Rombolà Giuseppe, Fogazzi Giovanni Battista, Rosatelli Cristina, Martinhago Ciro Dresch, Carmellini Mario, Mancini Roberta, Di Costanzo Giuseppina, Longo Ilaria, Renieri Alessandra, Mari Francesca
Medical Genetics, Department of Molecular Biology, University of Siena, Siena, Italy.
Nephrol Dial Transplant. 2009 May;24(5):1464-71. doi: 10.1093/ndt/gfn681. Epub 2009 Jan 7.
Alport syndrome is a clinically and genetically heterogeneous nephropathy characterized by glomerular basement membrane lesions often associated with hearing loss and ocular anomalies. While the X-linked and the autosomal recessive forms are well known, the autosomal dominant form is not well acknowledged.
We have clinically investigated 38 patients with a diagnosis of autosomal dominant Alport syndrome belonging to eight different families. The analysis of the COL4A4 gene was performed by denaturing high performance liquid chromatography and automated DNA sequencing.
In our cohort of patients, only 24.3% (9/37) reached end-stage renal disease, at the mean age of 51.2 years. Four patients had hearing loss (13.3%) and none ocular changes. Molecular analysis revealed eight novel private COL4A4 gene mutations: three frameshift, three missense and two splice-site mutations.
These data indicate autosomal dominant Alport syndrome as a disease with a low risk of ocular and hearing anomalies but with a significant risk to develop renal failure although at an older age than the X-linked form. We were unable to demonstrate a genotype-phenotype correlation. Altogether, these data make difficult the differential diagnosis with the benign familial haematuria due to heterozygous mutations of COL4A4 and COL4A3, especially in young patients, and with the X-linked form of Alport syndrome in families where only females are affected. A correct diagnosis and prognosis is based on a comprehensive clinical investigation in as many family members as possible associated with a broadly formal genetic analysis of the pedigree.
Alport综合征是一种临床和遗传异质性肾病,其特征为肾小球基底膜病变,常伴有听力丧失和眼部异常。虽然X连锁型和常染色体隐性型已广为人知,但常染色体显性型却未得到充分认识。
我们对来自8个不同家庭的38例诊断为常染色体显性Alport综合征的患者进行了临床研究。通过变性高效液相色谱法和自动DNA测序对COL4A4基因进行分析。
在我们的患者队列中,仅24.3%(9/37)达到终末期肾病,平均年龄为51.2岁。4例患者有听力丧失(13.3%),无眼部改变。分子分析发现8个新的COL4A4基因私人突变:3个移码突变、3个错义突变和2个剪接位点突变。
这些数据表明,常染色体显性Alport综合征是一种眼部和听力异常风险较低,但发生肾衰竭风险较高的疾病,尽管其发病年龄比X连锁型晚。我们未能证明基因型与表型之间的相关性。总之,这些数据使得与因COL4A4和COL4A3杂合突变导致的良性家族性血尿进行鉴别诊断变得困难,尤其是在年轻患者中,并且在仅女性受影响的家庭中与X连锁型Alport综合征进行鉴别诊断也很困难。正确的诊断和预后基于对尽可能多的家庭成员进行全面的临床研究,并结合对家系进行广泛的正式遗传分析。